Opentrons raises $40 million to standardize AI-driven science on its lab robots
Image: Opentrons (2023 Flex launch image, via TechCrunch) · press-kit
Opentrons announced a $40 million Series E on 29 October 2026, led by healthcare investor Avego, for its open lab automation robots.
Opentrons announced a $40 million Series E round on 29 October 2026. The round was led by Avego, a healthcare investor, with participation from BroadOak Capital Partners. Existing investors named in the release include SoftBank Vision Fund and Khosla Ventures.
The company makes open, API-driven laboratory robots. It says more than 11,000 of them are deployed in over 80 countries, and that its customers include 90 percent of the top 20 global pharmaceutical companies, 14 of the top 15 global biopharma companies and every top-20 US research university. These are company claims.
Opentrons says the money will go to robotics, software and data infrastructure, AI-driven experiment execution, new automation capabilities, new markets and geographies, faster protocol development and deeper integration with the wider lab automation ecosystem.
The release does not give the total raised to date or a valuation. It describes the aim as standardizing biological experimentation on its robots, so that AI systems can run experiments in the physical lab.
Sources
- Opentrons Primary source
